Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics (STARRING)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03288012 |
|
Recruitment Status : Unknown
Verified August 2018 by Sanquin Research & Blood Bank Divisions.
Recruitment status was: Recruiting
First Posted : September 19, 2017
Last Update Posted : July 19, 2019
|
Sponsor:
Sanquin Research & Blood Bank Divisions
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Radboud University Medical Center
HagaZiekenhuis
Erasmus Medical Center
Information provided by (Responsible Party):
Sanquin Research & Blood Bank Divisions
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | June 1, 2021 |
| Estimated Study Completion Date : | December 31, 2021 |